CHRM3 and type 2 diabetes mellitus: Further mechanistic studies demonstrated that BZYQF can reduce glucose and lipid accumulation, enhance acetylcholine content, and improve pathological lesions and inflammation, as well as increasing the expression of signaling molecules—including PKA, IP3R, β1-AR, AQP5, CHRM3, and AMY1—in the salivary secretion pathway in the PG and SMG of T2DM rats.